Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Zynteglo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Zynteglo market is seeing substantial growth, driven by factors such as the increasing prevalence of transfusion-dependent beta-thalassemia and advances in gene therapy. During the historic period, growth stemmed from the constraints of traditional blood transfusions, expansion of genetic disease centers, and early regulatory approvals for gene therapies.
Looking ahead, the market is set to benefit from the commercialization of gene editing therapies, rising investment in rare disease treatments, and an expanding personalized medicine infrastructure. There's a growing focus on curative hematology solutions and increased healthcare funding for genetic disorders.
The demand for Zynteglo is largely propelled by the rising incidence of thalassemia. This genetic disorder results in inadequate hemoglobin production, leading to anemia. Factors like high carrier rates in certain populations, consanguineous marriages, and improved diagnosis rates contribute to the increased incidence of thalassemia. Zynteglo offers a one-time gene therapy that enables patients to produce healthy hemoglobin, potentially reducing the dependency on regular blood transfusions. As of 2023, there were approximately 3,665 cases of beta-thalassemia in the US, translating to 1.07 per 100,000 people, underscoring the demand for Zynteglo.
The Zynteglo market also benefits from growth in healthcare infrastructure, driven by advancements in medical technology, government investments, and an increase in chronic diseases cases. Enhanced infrastructure supports advanced treatments like Zynteglo, providing comprehensive care from diagnosis through therapy. In the UK, healthcare infrastructure investments rose 18% year-on-year in 2024, reaching £4.8 billion, supporting the anticipated market growth.
Companies in the Zynteglo market are focusing on technological advancements to scale up commercialization and implement gene therapies in real-world settings. This includes optimizing patient processes, supply-chain readiness, and establishing center-of-excellence networks for effective delivery of therapies. For instance, bluebird bio, Inc. completed 26 patient starts in 2023 across its commercial portfolio, including 20 for Zynteglo, demonstrating their operational capability for scaling gene therapies.
Regionally, North America led the Zynteglo market in 2025. However, import tariffs impact the market by increasing costs for imported components crucial for gene therapy manufacturing. This is pushing treatment centers to explore local manufacturing solutions. Despite these challenges, the Zynteglo market remains robust, supported by a comprehensive research report detailing market statistics, global size, regional shares, and trend analyses crucial for industry stakeholders.
Zynteglo offers hope to beta-thalassemia patients by modifying stem cells to produce functional hemoglobin, reducing the reliance on blood transfusions. The market covers the sales of autologous gene therapy, one-time curative therapies, and cell-based products, representing 'factory gate' values. This market encompasses revenues from sales, grants, and donations.
Report Scope:
- Markets Covered: Beta-Thalassemia; Sickle Cell Disease
- Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- End Users: Adult; Pediatric; Geriatric
- Companies Mentioned: Bluebird bio Inc
- Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
For more information about this report visit https://www.researchandmarkets.com/r/tffri1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
